{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diverticular-disease/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"f2cde7d6-3b3a-5b9f-bf9c-9c7445a1ae6f","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field f7eea5a5-663a-488e-87de-ab1b00e4c5d0 --><h2>Trimethoprim</h2><!-- end field f7eea5a5-663a-488e-87de-ab1b00e4c5d0 -->","summary":"","htmlStringContent":"<!-- begin item a99951e0-bce9-4351-ab87-ab1b00e4c5b4 --><!-- end item a99951e0-bce9-4351-ab87-ab1b00e4c5b4 -->","topic":{"id":"94c44346-c791-5b97-9e45-bacb8fe90589","topicId":"eee234d5-c667-4944-95d2-a45f5e032286","topicName":"Diverticular disease","slug":"diverticular-disease","lastRevised":"Last revised in January 2021","chapters":[{"id":"5bcd7ed5-7ab4-57a1-a517-99ee8bb7b2d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5abc06b8-fef4-5d67-81ce-ee1c71284864","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"71ba91f6-898b-5f69-bd52-93f3b1892ad6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7460514b-3977-52be-9e12-06486604b194","slug":"changes","fullItemName":"Changes"},{"id":"909831b0-6f3c-5e85-8263-a5e1785b8a49","slug":"update","fullItemName":"Update"}]},{"id":"fcd203c7-5d1a-5fcc-ab90-5286ab76bd2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2cbe6fe5-f942-566e-9136-915145ba8517","slug":"goals","fullItemName":"Goals"},{"id":"ffcabc25-6966-526d-8382-a5fcf56185ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"dc0b24e2-e0db-5829-baf5-a7aae6d5ab67","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b5dcfe41-ec7c-5a9f-bc96-229f8b818a77","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d9311147-ff58-5778-bb86-c0249937ef45","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b76632c-4924-5c26-99ab-549b62bb2f73","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"435ea69d-fb08-554b-b803-cc64d393575b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"12666ff2-dbf6-51be-b83a-78c0d4aa12e3","slug":"definition","fullItemName":"Definition"},{"id":"3a4412ce-ae17-58e7-8460-9ab759755b96","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"11908cbc-fb2b-525e-9bed-e9da60b6ad8a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2efdd449-ac81-531a-9514-72e57632cf72","slug":"complications","fullItemName":"Complications"},{"id":"2bb98737-1604-5f47-8f96-27003159f003","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b9740a9c-8383-57e1-8cc6-7fea164147c7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"411e61cd-aad7-5e40-bf27-38061aae07cb","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"21f90600-3a9d-5e53-92e4-7305f17db5aa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c90663d3-95e7-5f18-9718-27a43a51abbf","fullItemName":"Management","slug":"management","subChapters":[{"id":"43142f56-faaf-50dc-a1b7-1d4fb26d1a5e","slug":"diverticulosis","fullItemName":"Scenario: Diverticulosis"},{"id":"a1baccf2-7945-577b-b755-eff86d33201c","slug":"diverticular-disease","fullItemName":"Scenario: Diverticular disease"},{"id":"0c23dfbe-5e71-5eeb-9b03-6b3377f49225","slug":"acute-diverticulitis","fullItemName":"Scenario: Acute diverticulitis"}]},{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2bc84877-2507-5c10-af40-fef065820ce1","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"ba178fdc-1c2f-58e1-aec7-b1f903ed5207","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"524ca556-9a60-542a-9102-901470ef4882","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"463ca371-3542-5765-8350-4a0a640f0cae","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"231102c0-511c-5785-ac06-8720d28571cb","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f2cde7d6-3b3a-5b9f-bf9c-9c7445a1ae6f","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"8b942243-eed9-557a-9678-01f6c77e2b91","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ccd6405-b8ec-557d-9d70-bce3f43accbd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"544db73d-5bf7-5ac9-81f4-784210ec7343","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2fb4d8d-7ad7-55ef-837b-a9faa80ba34d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8cbe5c96-baf1-5b25-af5c-6f36a3d9ea3c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7518d3a3-e804-5074-908b-2b9f984cbf60","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e84d6049-8652-59d8-a02d-c49972295f21","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1de75d4a-a4c8-5742-add9-eabcb6711bcb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b30de8ba-1b8a-5f97-83ef-4d6ebc76ae50","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8e474758-ffc3-591e-97cc-6d920768cda0","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 5d99f144-05f4-44d4-93bd-ab1b00eb9bdb --><h3>Cautions and contraindications</h3><!-- end field 5d99f144-05f4-44d4-93bd-ab1b00eb9bdb -->","summary":"","htmlStringContent":"<!-- begin item 327960b8-e5eb-4152-ac87-ab1b00eb9bc4 --><!-- begin field e14c1774-862c-41bc-b267-ab1b00eb9bdb --><ul><li><strong>Do not prescribe trimethoprim in:</strong><ul><li>People with severe hepatic insufficiency, or severe renal insufficiency.</li><li>People with megaloblastic anaemia or other blood dyscrasias.</li><li>Premature infants or children aged under 4 months.</li><li>Women who are pregnant.</li></ul></li><li><strong>Prescribe trimethoprim with caution in people:</strong><ul><li>With impaired renal function.</li><li>With hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>With acute porphyria.</li><li>Predisposed to folate deficiency — because of the potential anti-folate effect of trimethoprim, there is a risk of further exacerbating folate deficiency in people who are folate deficient, or who are predisposed to folate deficiency (for example elderly people), or who are taking folate antagonists.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 74, 2017</a>]</p><!-- end field e14c1774-862c-41bc-b267-ab1b00eb9bdb --><!-- end item 327960b8-e5eb-4152-ac87-ab1b00eb9bc4 -->","subChapters":[]},{"id":"828557c2-3f9a-5142-b306-93ea5f028b48","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f1a3ae43-377e-47b0-8703-ab1b00ebe717 --><h3>Adverse effects</h3><!-- end field f1a3ae43-377e-47b0-8703-ab1b00ebe717 -->","summary":"","htmlStringContent":"<!-- begin item e10ec01d-6caf-4eda-9f84-ab1b00ebe6fe --><!-- begin field 1eaddfb5-0a90-4f14-b2fd-ab1b00ebe717 --><ul><li><strong>Blood disorders</strong> — leucopenia, megaloblastic anaemia, thrombocytopenia, agranulocyctosis, hyperkalaemia (particularly in the eldery and in HIV patients), methaemoglobinaemia.</li><li><strong>Gastrointestina</strong>l — nausea, vomiting, glossitis.</li><li><strong>Nervous system</strong> — aseptic meningitis (frequency unknown).</li><li><strong>Skin</strong> — Pruritus, and skin rashes (common).<ul><li><strong>Rarely: </strong>Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura, angioedema.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Liver enzyme disturbances, cholestatic jaundice.</li><li>Myalgia.</li><li>Raised serum creatinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 74, 2017</a>]</p><!-- end field 1eaddfb5-0a90-4f14-b2fd-ab1b00ebe717 --><!-- end item e10ec01d-6caf-4eda-9f84-ab1b00ebe6fe -->","subChapters":[]},{"id":"a29dc200-ae6b-5d73-bfe4-8c396778727c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 592799ac-d1ca-4959-b6b8-ab1b00ec54cb --><h3>Drug interactions</h3><!-- end field 592799ac-d1ca-4959-b6b8-ab1b00ec54cb -->","summary":"","htmlStringContent":"<!-- begin item dee1032a-93f1-4c3c-bdad-ab1b00ec54b1 --><!-- begin field 8c26c2fa-81db-4f65-a96a-ab1b00ec54cb --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and </strong><strong>angiotensin-II receptor antagonists </strong><strong>AIIRAs</strong> — there may be an increased risk of hyperkalaemia with the concurrent use of these drugs and trimethoprim. Monitor potassium concentrations. </li><li><strong>Azathioprine and mercaptopurine – </strong>increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li><strong>Ciclosporin </strong>— serum creatinine levels may be increased. Possible increased risk of nephrotoxicity. Monitor renal function closely.</li><li><strong>Coumarins (warfarin) —</strong> the anticoagulant effect of coumarins may be potentiated. Monitor international normalised ratio (INR) and adjust dose accordingly.</li><li><strong>Digoxin</strong> — digoxin levels may be increase in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li><strong>Diuretics —</strong> hyperkalaemia may be exacerbated by concomitant administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li><strong>Methotrexate (a folate antagonist) </strong>– there is an increased risk of haematologic adverse effects. Several cases of bone marrow suppression have been reported (some fatal). Full blood count should be monitored routinely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of trimethoprim.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Phenytoin </strong>– phenytoin levels may be increase if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">FSRH, 2017</a>]</p><!-- end field 8c26c2fa-81db-4f65-a96a-ab1b00ec54cb --><!-- end item dee1032a-93f1-4c3c-bdad-ab1b00ec54b1 -->","subChapters":[]},{"id":"9a4aa56f-6474-562e-9259-cfda1d87cbd2","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 00c0896c-d988-42c4-8894-ab1b00ecb8fc --><h3>Pregnancy and breastfeeding</h3><!-- end field 00c0896c-d988-42c4-8894-ab1b00ecb8fc -->","summary":"","htmlStringContent":"<!-- begin item 277e5ae4-660e-421e-ad37-ab1b00ecb8e5 --><!-- begin field d690db1c-a663-47f8-ba82-ab1b00ecb8fc --><ul><li><strong>Pregnancy</strong><ul><li>There is a teratogenic risk in the first trimester of pregnancy. The manufacturer advises that it should not be used in women who are pregnant.</li><li>In women with normal folate status, who are well nourished, use of trimethoprim for a short period is unlikely to induce folate deficiency, however, it should be avoided if folate deficiency is suspected.</li><li>If trimethoprim is recommended for use during the first trimester:<ul><li>Ensure the woman is taking a folic acid supplement.</li><li>Prescribe folic acid 5 mg daily.</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Trimethoprim is excreted in breastmilk, but is not known to be harmful.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diverticular-disease/references/\">NPIS, 2017</a>] </p><!-- end field d690db1c-a663-47f8-ba82-ab1b00ecb8fc --><!-- end item 277e5ae4-660e-421e-ad37-ab1b00ecb8e5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}